Compare HAFC & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HAFC | ODTX |
|---|---|---|
| Founded | 1982 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 972.5M | 875.1M |
| IPO Year | 2000 | 2025 |
| Metric | HAFC | ODTX |
|---|---|---|
| Price | $32.44 | $20.73 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $32.17 | N/A |
| AVG Volume (30 Days) | ★ 253.1K | 173.5K |
| Earning Date | 04-21-2026 | N/A |
| Dividend Yield | ★ 3.75% | N/A |
| EPS Growth | ★ 22.44 | N/A |
| EPS | ★ 1.54 | N/A |
| Revenue | ★ $270,165,000.00 | N/A |
| Revenue This Year | $18.65 | N/A |
| Revenue Next Year | $7.28 | N/A |
| P/E Ratio | $21.10 | ★ N/A |
| Revenue Growth | ★ 15.28 | N/A |
| 52 Week Low | $22.85 | $15.10 |
| 52 Week High | $33.50 | $23.08 |
| Indicator | HAFC | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.04 | 56.19 |
| Support Level | $31.45 | $15.10 |
| Resistance Level | $32.70 | N/A |
| Average True Range (ATR) | 0.43 | 1.74 |
| MACD | 0.02 | 0.15 |
| Stochastic Oscillator | 76.77 | 56.51 |
Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.